Abstract
Abstract Date Presented 04/20/2023 Accurate estimates of the minimal clinically significant difference (MCID) of the Upper Extremity scale of the Fugl–Myer Assessment are essential for determining the effectiveness of interventions provided to stroke survivors in the chronic phase with residual severe upper extremity hemiparesis. Previously established values cannot be generalized to stroke survivors in other phases of recovery and with differing severity of residual hemiparesis due to the diversity in level of impairment. Primary Author and Speaker: Elliot Barden Additional Authors and Speakers: Kyle O'Laughlin Contributing Authors: Ela Plow, Jayme Knutson, Xiaofeng Wang, Kaitlin Perlic
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
